Uncover the hidden connection between bacterial infections and cancer progression—specifically how Mycobacterium bovis not only infects hosts but may also drive cancer-related changes in lung tissue. And here’s where it gets controversial: a host protein called RBMX2 appears to be a key player, amplifying bacterial invasion and triggering processes associated with cancer development. If you’ve ever wondered how infectious agents could influence tumor biology, this detailed discovery might change your perspective.**
Tuberculosis (TB) is a complex disease resulting from the interplay between the pathogen, the host's immune system, and environmental factors. In 2022, approximately 10.6 million individuals worldwide were affected by TB, leading to nearly 1.3 million deaths. In regions where zoonotic TB is common, the bacteria Mycobacterium bovis accounts for roughly 10% of human TB cases. The ability of M. tuberculosis and M. bovis to evade immune responses and enter a dormant, latent phase complicates efforts to understand how the host ultimately responds to infection.
Recent research points to a provocative link: persistent bacterial infections like TB might not just be innocent bystanders but could actively promote cellular transformations leading to cancer, especially in lung tissue. Chronic inflammation caused by long-lasting infections can create an environment conducive to cancer development through processes such as epithelial–mesenchymal transition (EMT), a biological change that enables epithelial cells to acquire mobility and invasive traits associated with metastasis. Yet, the underlying molecular players connecting infection and cancer remain largely uncharted territory.
This is where RBMX2, an RNA-binding protein, enters the scene—the host factor newly identified as facilitating M. bovis infection and manipulating host cell behavior. Our previous studies indicated RBMX2's role in regulating alternative splicing and apoptosis after M. bovis exposure. Significantly, its homolog, RBMX, has shown dual roles in cancer—sometimes promoting tumor growth, other times suppressing it, depending on tissue type. For example, RBMX is overexpressed in liver and T-cell lymphomas but reduced in pancreatic cancer, highlighting it as a vessel of complex regulatory functions.
In this study, using a sophisticated CRISPR-based genetic screening approach, we pinpointed RBMX2 as a vital host factor. When we knocked out RBMX2, cells exhibited increased resistance to M. bovis, suggesting that RBMX2 somehow facilitates bacterial infection. Further bioinformatic and experimental analyses revealed that RBMX2 enhances M. bovis adhesion and invasion by modulating cell adhesion molecules and tight junctions—proteins critical for maintaining the epithelial barrier. This process involves the activation of p65, a component of the NF-κB pathway, which not only disrupts cell junctions but also promotes the expression of MMP-9, a matrix-degrading enzyme that triggers EMT.
Our data show that RBMX2's influence extends beyond bacterial invasion. It actively regulates genes involved in cell adhesion, extracellular matrix interaction, and signaling pathways like TGF-beta—pathways closely tied to tumor progression. When RBMX2 expression was reduced, tight junctions in host epithelial cells remained intact, inflammation markers decreased, and the cells resisted transformation into more invasive states. Conversely, elevated RBMX2 levels—a feature observed in lung adenocarcinoma and squamous cell carcinoma tissues—correlate with increased EMT markers and pro-metastatic behaviors, suggesting a path from infection to cancer that RBMX2 may help facilitate.
Additionally, functional assays demonstrated that RBMX2 promotes the attachment, entry, and survival of M. bovis inside host cells by weakening cell junctions and enhancing pathogen invasion pathways. These effects were observed not only for M. bovis but also for attenuated BCG strains and other mycobacteria like M. smegmatis, as well as unrelated pathogens such as Salmonella and E. coli, indicating RBMX2's broad role in host-pathogen interactions, especially in respiratory infections.
Furthermore, in human lung carcinoma cells with high RBMX2 expression, suppression of RBMX2 reduced EMT and invasion, emphasizing its regulatory importance across species. Epidemiological data add weight to these findings: RBMX2 is notably overexpressed in lung tumors and seems to influence metabolites linked to tumor growth and cell motility.
A particularly intriguing aspect is how RBMX2 interacts with the NF-κB pathway component p65. Molecular docking and chromatin immunoprecipitation experiments suggest that p65 can directly bind to the RBMX2 promoter, enhancing its expression. RBMX2, in turn, promotes p65 activity, creating a feedback loop that amplifies both infection and EMT-driven tumor progression. Activation of p65 increases MMP-9 expression, which facilitates EMT, cell migration, and invasion—hallmarks of metastatic cancer.
But here's the controversy: While it appears that bacterial infection upregulates RBMX2, promoting both immune evasion and EMT, some might argue that such host proteins have evolved as part of a complex immune strategy or cellular adaptation rather than as malignant drivers. Is RBMX2 a victim of infection, or is it an unwitting accomplice in cancer progression? Can targeting RBMX2 prevent both TB infection and lung cancer, or would that impair essential cellular functions?
And this is the part most people miss: The discovery that a single host factor like RBMX2 operates at the crossroads of infectious disease and cancer challenges us to rethink how chronic infections influence long-term health outcomes. Could modulating RBMX2 provide a dual-purpose therapeutic strategy—bolstering resistance to bacterial invasion while preventing EMT-driven tumor formation? Or does its dual role pose risks of unintended consequences?
In conclusion, RBMX2 emerges as a critical regulator that both aids M. bovis infection and promotes EMT, potentially serving as a bridge linking TB to lung carcinogenesis. These insights open the door to novel therapeutic approaches targeting host factors to combat both infectious disease and cancer. But as with all such findings, the question remains: is RBMX2 a promising target or a complex puzzle piece in a broader host-pathogen-tumor interaction network? Your thoughts—agree or disagree? Share your perspective in the comments!**
